Dr. G Thomas Thomas Budd, MD

Dr. Budd practices at Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation.

Dr. Budd's NPI, 1457315673, was assigned on April 14, 2006. Dr. Budd graduated from University of Kansas School of Med (KC/Wich/Sal) in 1977. Dr. Budd holds Ohio license 35044178B.

Dr. Budd's primary practice is Cleveland Clinic Main Campus, at 9500 Euclid Avenue, Cleveland, OH 44195 in Cuyahoga County. The practice phone is (216) 952-9829.

Dr. Budd's primary practice is Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation. Dr. Budd is also affiliated with Fairview Hospital. The medical group on file is Cleveland Clinic. Dmand AI also links Dr. Budd to 3 more hospitals and 2 clinical labs, each named with a free account. Dr. Budd's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Budd practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Budd's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Budd is licensed in Ohio.

CMS data shows 253 Medicare services from Dr. Budd across 5 procedure codes in 2024, for 125 Medicare patients. Medicare paid $15,330 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 125 Medicare patients who saw Dr. Budd in 2024. The largest group is 65 to 74, with 71 patients. 73% of them have cancer, and 67% have high cholesterol. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Budd's median patient age at 63, with 91% women.

In 2024, Dr. Budd wrote 401 Medicare Part D claims for 80 patients. 78% of them were for generic drugs. CMS names the drug for 245 of them, across 9 drugs with 11 or more claims each, at $1,206,334 in total drug cost. In 2023, CMS named 335 claims across 9 drugs.

Dr. Budd accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Budd as offering telehealth.

Dmand AI links 38 papers to Dr. Budd, published from 2011 to 2025. 2017 was the busiest year, with 5. The most frequent topics are Breast Neoplasms, Antineoplastic Agents and Antineoplastic Combined Chemotherapy Protocols. Dr. Budd has published most often in Breast Cancer Res Treat. Dr. Budd's most frequent co-authors are Halle C. Moore, MD, Dawn Lauryn Hershman, MD and Julie R. Gralow, MD.

Dmand AI links Dr. Budd to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Triple Negative Breast Neoplasms, Neoplasm, Residual and Breast Neoplasms.

CMS Open Payments shows 28 general payments to Dr. Budd from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 43% of the total. Deciphera Pharmaceuticals Inc. paid the most, $8,124.

Dr. Budd graduated from University of Kansas School of Med (KC/Wich/Sal) in 1977.